Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 10/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.45 |
| ▸ | SRC | P12931 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.45 |
| ▸ | AVPR1B | P47901 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3341669 | 0.93 | MAPK14 (0.52) | MAPK14MCHR1 | |
| SCHEMBL3339442 | 0.92 | MAPK14 (0.51) | MAPK14MCHR1 | |
| SCHEMBL1140062 | 0.90 | MAPK14 (0.59) | MAPK14AVPR1B | |
| SCHEMBL1139873 | 0.87 | MAPK14 (0.63) | MAPK14AVPR1B | |
| SCHEMBL3108493 | 0.86 | MAPK14 (0.63) | MAPK14AVPR1BSMN1; SMN2GAA | |
| SCHEMBL3118904 | 0.86 | MAPK14 (0.51) | MAPK14AVPR1B | |
| SCHEMBL3341342 | 0.86 | MAPK14 (0.63) | MAPK14 | |
| SCHEMBL3110205 | 0.85 | MAPK14 (0.51) | MAPK14AVPR1BSMN1; SMN2GAA | |
| SCHEMBL1399861 | 0.82 | ALDH1A1 (0.48) | MAPK14KDM4EALDH1A1MCHR1SMN1; SMN2 | |
| SCHEMBL1140310 | 0.82 | MAPK14 (0.65) | MAPK14AVPR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100152169-A1 | 4-OXOQUINAZOLIN-3-YL BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CYTOKINE DISEASES | ASTRAZENECA AB (SE) | 2010-06-17 | — | — | US | disclosed |
| US-7696215-B2 | 4-oxoquinazolin-3-yl benzamide derivatives for the treatment of cytokine diseases | ASTRAZENECA AB (SE) | 2010-04-13 | — | — | US | disclosed |
| US-20090124604-A1 | 4-OXOQUINAZOLIN-3-YL BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CYTOKINE DISEASES | ASTRAZENECA AB (SE) | 2009-05-14 | — | — | US | disclosed |
| EP-1856062-A1 | 4-OXOQUINAZOLIN-3-YL BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CYTOKINE MEDIATED DISEASES | AstraZeneca AB (SE) | 2007-11-21 | — | — | EP | disclosed |
| WO-2006090143-A1 | 4-0X0QUINAZ0LIN-3-YL BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CYTOKINE DISEASES | ASTRAZENECA AB (SE) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152169-A1 | 4-OXOQUINAZOLIN-3-YL BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CYTOKINE DISEASES | IL2, IL1A, IL2RA | MAPK14 1418/4885FGFR1 382/4885SRC 1921/4885 |
| US-20090124604-A1 | 4-OXOQUINAZOLIN-3-YL BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CYTOKINE DISEASES | IL2, IL1A, IL1B | MAPK14 1400/4885FGFR1 380/4885SRC 1689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.